Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by δ9-tetrahydrocannabinol in human CD4+ T cells

Toxicology and Applied Pharmacology

Volumn 273, Issue 1, 2013, Pages 209-218

  Ngaotepprutaram, Thitirat ^a,b   Kaplan, Barbara L F ^a,b   Kaminski, Norbert E ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

9 tetrahydrocannabinol ( 9 THC); CD40L; Intracellular calcium; NF B; NFAT; T cell receptor signaling

Indexed keywords

CD3 ANTIBODY; CD40 LIGAND; DRONABINOL; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHOSPHOLIPASE C GAMMA1; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE B; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CALCIUM CELL LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

Δ(9)-TETRAHYDROCANNABINOL (Δ(9)-THC); CD40L; INTRACELLULAR CALCIUM; NFΚB; NFAT; T CELL-RECEPTOR SIGNALING;

ANIMALS; ANTIGENS, CD28; CALCIUM; CANNABINOIDS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; DRONABINOL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84880364900     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.08.023     Document Type: Article

References (68)

1. Appleman L.J., van Puijenbroek A.A., Shu K.M., Nadler L.M., Boussiotis V.A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 2002, 168:2729-2736.
2. Bartelt R.R., Cruz-Orcutt N., Collins M., Houtman J.C. Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells. PLoS One 2009, 4:e5430.
3. Boomer J.S., Green J.M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2010, 2:a002436.
4. Borner C., Smida M., Hollt V., Schraven B., Kraus J. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J. Biol. Chem. 2009, 284:35450-35460.
5. Bornheim L.M., Kim K.Y., Li J., Perotti B.Y., Benet L.Z. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab. Dispos. 1995, 23:825-831.
6. Bromley S.K., Burack W.R., Johnson K.G., Somersalo K., Sims T.N., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. The immunological synapse. Annu. Rev. Immunol. 2001, 19:375-396.
7. Chatzigeorgiou A., Lyberi M., Chatzilymperis G., Nezos A., Kamper E. CD40/CD40L signaling and its implication in health and disease. Biofactors 2009, 35:474-483.
8. Chen K., Huang J., Gong W., Zhang L., Yu P., Wang J.M. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell. Mol. Immunol. 2006, 3:163-169.
9. Chen E., Staudt L.M., Green A.R. Janus kinase deregulation in leukemia and lymphoma. Immunity 2012, 36:529-541.
10. Chen W., Kaplan B.L., Pike S.T., Topper L.A., Lichorobiec N.R., Simmons S.O., Ramabhadran R., Kaminski N.E. Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120. J. Leukoc. Biol. 2012, 92:1093-1102.
11. Christophersen A.S. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J. Anal. Toxicol. 1986, 10:129-131.
12. Condie R., Herring A., Koh W.S., Lee M., Kaminski N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem. 1996, 271:13175-13183.
13. Crist S.A., Sprague D.L., Ratliff T.L. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood 2008, 111:3553-3561.
14. Cron R.Q. CD154 transcriptional regulation in primary human CD4 T cells. Immunol. Res. 2003, 27:185-202.
15. Croxford J.L., Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. J. Neuroimmunol. 2005, 166:3-18.
16. Daoussis D., Andonopoulos A.P., Liossis S.N. Targeting CD40L: a promising therapeutic approach. Clin. Diagn. Lab. Immunol. 2004, 11:635-641.
17. Faubert Kaplan B.L., Kaminski N.E. Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. Int. Immunopharmacol. 2003, 3:1503-1510.
18. Faubert B.L., Kaminski N.E. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J. Leukoc. Biol. 2000, 67:259-266.
19. 2+/calcineurin signalling in cells of the immune system. Biochem. Biophys. Res. Commun. 2003, 311:1117-1132.
20. Ford G.S., Barnhart B., Shone S., Covey L.R. Regulation of CD154 (CD40 ligand) mRNA stability during T cell activation. J. Immunol. 1999, 162:4037-4044.
21. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 2002, 109:295-299.
22. Fuleihan R., Ramesh N., Horner A., Ahern D., Belshaw P.J., Alberg D.G., Stamenkovic I., Harmon W., Geha R.S. Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J. Clin. Invest. 1994, 93:1315-1320.
23. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
24. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003, 42:327-360.
25. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 2003, 3:745-755.
26. Herring A.C., Kaminski N.E. Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J. Pharmacol. Exp. Ther. 1999, 291:1156-1163.
27. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 1992, 16:276-282.
28. Jan T.R., Rao G.K., Kaminski N.E. Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol. Pharmacol. 2002, 61:446-454.
29. Kaminski D.A., Lee B.O., Eaton S.M., Haynes L., Randall T.D. CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells. Immunology 2009, 127:373-385.
30. Kaplan B.L., Ouyang Y., Rockwell C.E., Rao G.K., Kaminski N.E. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J. Leukoc. Biol. 2005, 77:966-974.
31. Kaplan B.L., Springs A.E., Kaminski N.E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem. Pharmacol. 2008, 76:726-737.
32. 9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin. Chem. 2011, 57:66-75.
33. Kelly P., Jones R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J. Anal. Toxicol. 1992, 16:228-235.
34. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
35. Landrigan A., Wong M.T., Utz P.J. CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J. Immunol. 2011, 187:3033-3043.
36. Lee B.O., Haynes L., Eaton S.M., Swain S.L., Randall T.D. The biological outcome of CD40 signaling is dependent on the duration of CD40 ligand expression: reciprocal regulation by interleukin (IL)-4 and IL-12. J. Exp. Med. 2002, 196:693-704.
37. Lewis R.S., Cahalan M.D. Potassium and calcium channels in lymphocytes. Annu. Rev. Immunol. 1995, 13:623-653.
38. Lindgren H., Axcrona K., Leanderson T. Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2. J. Immunol. 2001, 166:4578-4585.
39. -δδCT method. Methods 2001, 25:402-408.
40. Lu H., Crawford R.B., North C.M., Kaplan B.L., Kaminski N.E. Establishment of an immunoglobulin M antibody-forming cell response model for characterizing immunotoxicity in primary human B cells. Toxicol. Sci. 2009, 112:363-373.
41. 9-tetrahydrocannabinol. J. Leukoc. Biol. 2009, 85:322-329.
42. McDyer J.F., Li Z., John S., Yu X., Wu C.Y., Ragheb J.A. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J. Immunol. 2002, 169:2736-2746.
43. Mendez-Samperio P., Ayala H., Vazquez A. NF-kappaB is involved in regulation of CD40 ligand expression on Mycobacterium bovis bacillus Calmette-Guerin-activated human T cells. Clin. Diagn. Lab. Immunol. 2003, 10:376-382.
44. + T cells. J. Neuroimmune Pharmacol. 2012, 7:969-980.
45. NIDA Marijuana-An Update from the National Institute on Drug Abuse 2011, Public Information and Liaison Branch. U. S. D. o. H. a. H. Services (Ed.).
46. Nusslein H.G., Frosch K.H., Woith W., Lane P., Kalden J.R., Manger B. Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. Eur. J. Immunol. 1996, 26:846-850.
47. Ouyang Y., Kaminski N.E. Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch. Toxicol. 1999, 73:1-6.
48. Pietravalle F., Lecoanet-Henchoz S., Blasey H., Aubry J.P., Elson G., Edgerton M.D., Bonnefoy J.Y., Gauchat J.F. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J. Biol. Chem. 1996, 271:5965-5967.
49. 2-glycerol, a putative metabolite of 2-arachidonyl glycerol and a peroxisome proliferator-activated receptor gamma ligand, modulates nuclear factor of activated T cells. J. Pharmacol. Exp. Ther. 2012, 342:816-826.
50. Rao G.K., Kaminski N.E. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J. Pharmacol. Exp. Ther. 2006, 317:820-829.
51. Rao G.K., Kaminski N.E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J. Leukoc. Biol. 2006, 79:202-213.
52. 9-tetrahydrocannabinol in resting T cells. J. Leukoc. Biol. 2004, 75:884-892.
53. Roy M., Waldschmidt T., Aruffo A., Ledbetter J.A., Noelle R.J. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. 1993, 151:2497-2510.
54. Schmitz M.L., Bacher S., Dienz O. NF-kappaB activation pathways induced by T cell costimulation. FASEB J. 2003, 17:2187-2193.
55. Schonbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 2001, 58:4-43.
56. Schonbeck U., Mach F., Libby P. CD154 (CD40 ligand). Int. J. Biochem. Cell Biol. 2000, 32:687-693.
57. Schubert L.A., King G., Cron R.Q., Lewis D.B., Aruffo A., Hollenbaugh D. The human gp39 promoter. Two distinct nuclear factors of activated T cell protein-binding elements contribute independently to transcriptional activation. J. Biol. Chem. 1995, 270:29624-29627.
58. Smiley S.T., Csizmadia V., Gao W., Turka L.A., Hancock W.W. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000, 70:415-419.
59. Snyder J.T., Shen J., Azmi H., Hou J., Fowler D.H., Ragheb J.A. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007, 109:5399-5406.
60. Springs A.E., Karmaus P.W., Crawford R.B., Kaplan B.L., Kaminski N.E. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 2008, 84:1574-1584.
61. Srahna M., Remacle J.E., Annamalai K., Pype S., Huylebroeck D., Boogaerts M.A., Vandenberghe P. NF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells. Clin. Exp. Immunol. 2001, 125:229-236.
62. Steiper M.E., Parikh S.J., Zichello J.M. Phylogenetic analysis of the promoter region of the CD40L gene in primates and other mammals. Infect. Genet. Evol. 2008, 8:406-413.
63. Tsytsykova A.V., Tsitsikov E.N., Geha R.S. The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J. Biol. Chem. 1996, 271:3763-3770.
64. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod. 1980, 43:169-234.
65. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
66. Wall M.E., Sadler B.M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin. Pharmacol. Ther. 1983, 34:352-363.
67. Yea S.S., Yang K.H., Kaminski N.E. Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J. Pharmacol. Exp. Ther. 2000, 292:597-605.
68. Yebra M., Klein T.W., Friedman H. Delta 9-tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci. 1992, 51:151-160.